Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 1;157(5):597-599.
doi: 10.1001/jamadermatol.2021.0356.

Use of Active Comparator Trials for Topical Medications in Dermatology

John Miller  1 , Sophia Ly  2 , Arash Mostaghimi  3 , John S Barbieri  4
Affiliations

Use of Active Comparator Trials for Topical Medications in Dermatology

John Miller et al. JAMA Dermatol. .

Abstract

This cross-sectional study evaluates the use and trends of active comparator trial designs in dermatology.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Mostaghimi receives consulting fees from Pfizer, hims, and 3derm, has equity in Lucid and hims, receives licensing fees from Pfizer, serves on the medical advisory board for hims, and is a clinical trial investigator for Incyte, Lilly, Aclaris, and Concert. No other disclosures were reported.

Figures

Figure.
Figure.. Trends in Use of Active Comparator Trials
See this image and copyright information in PMC

References

    1. Aitken M, Kleinrock M. Medicine use and spending in the U.S. IQVIA Institute for Human Data Science. Accessed November 3, 2019. https://www.iqvia.com/insights/the-iqvia-institute/reports/medicine-use-...
    1. Kirzinger A. KFF health tracking poll—February 2019: prescription drugs. Accessed January 19, 2021. https://www.kff.org/health-costs/poll-finding/kff-health-tracking-poll-f...
    1. Barbieri JS, Tan JKL, Adamson AS. Active comparator trial designs used to promote development of innovative new medications. Cutis. 2020;106(3):E4-E6. doi:10.12788/cutis.0067 - DOI - PubMed
    1. Olfson M, Marcus SC. Decline in placebo-controlled trial results suggests new directions for comparative effectiveness research. Health Aff (Millwood). 2013;32(6):1116-1125. doi:10.1377/hlthaff.2012.1353 - DOI - PubMed
    1. Drugs for Human Use, Subchapter D, 21 CFR §300.50 (2020).

Publication types

MeSH terms

Substances